Garrido, AliciaPérez Sisqués, LeticiaSimonet, CristinaCampoy Campos, GenísSolana Balaguer, JúliaMartín Flores, NúriaFernández, ManelSoto Gimeno, MartaObiang, DoninaCamara, AnaValldeoriola Serra, FrancescMuñoz, EstebanCompta, YaroslauPérez Navarro, EstherAlberch i Vié, Jordi, 1959-Tolosa, EduardoMartí Domènech, Ma. JosepEzquerra Trabalón, MarioMalagelada Grau, CristinaFernández Santiago, Rubén2023-03-012022-110364-5134https://hdl.handle.net/2445/194378The purpose of this study was to investigate whether differential phosphorylation states of blood markers can identify patients with LRRK2 Parkinson's disease (PD). We assessed phospho(P)-Ser-935-LRRK2 and P-Ser-473-AKT levels in peripheral blood cells from patients with G2019S LRRK2-associated PD (L2PD, n = 31), G2019S LRRK2 non-manifesting carriers (L2NMC, n = 26), idiopathic PD (iPD, n = 25), and controls (n = 40, total n = 122). We found no differences at P-Ser-935-LRRK2 between groups but detected a specific increase of P-Ser-473-AKT levels in all G2019S carriers, either L2PD or L2NMC, absent in iPD. Although insensitive to LRRK2 inhibition, our study identifies P-Ser-473-AKT as an endogenous candidate biomarker for peripheral inflammation in G2019S carriers using accessible blood cells. ANN NEUROL 2022;92:888-894.7 p.application/pdfengcc by nc-nd (c) Garrido, Alicia et al., 2022http://creativecommons.org/licenses/by-nc-nd/3.0/es/Malaltia de ParkinsonMutació (Biologia)Proteïnes portadoresCèl·lules sanguíniesNervis perifèricsParkinson's diseaseMutation (Biology)Carrier proteinsBlood cellsPeripheral nervesinfo:eu-repo/semantics/article7300222023-03-01info:eu-repo/semantics/openAccess35929078